|
|
|
| Clinical Efficacy of Xinmailong Injection Combined with Ribavirin in the Treatment of Viral Myocarditis with Cardiac Insufficiency |
| WANG Wen-jing |
| 155 Hospital of Kaifeng, Kaifeng Henan 475000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy of Xinmailong injection combined with Ribavirin in the treatment of viral Myocarditis with cardiac insufficiency. 【Methods】From September 2019 to November 2021, 106 patients with viral myocarditis and cardiac insufficiency caused by coxsackie virus infection in our hospital were selected and divided into an observation group and a control group according to the different treatment methods, with 53 cases in each group. The control group was treated with Ribavirin, and the observation group was treated with Xinmailong injection on the basis of the control group. The clinical efficacy, ultrasonic cardiac function indexes [left ventricular Ejection fraction (LVEF), left ventricular short axis shortening rate (FS), left ventricular end diastolic diameter (LVEDD), cardiac index (CI)], serum brain natriuretic peptide (BNP), Superoxide dismutase (SOD), Malondialdehyde (MDA), and glutathione (GSH) levels were compared between the two groups. 【Results】The total clinical effective rate of the observation group was 96.23% (51/53), which was higher than 81.13% (43/53) of the control group, with a statistically significant difference (P<0.05). After treatment, LVEF, FS, and CI in both groups were higher than before treatment, while the observation group was higher than the control group (P<0.05); The LVEDD of the two groups was lower than before treatment, while the observation group was lower than the control group (P<0.05); The levels of serum BNP, CK-MB, LDH, and CK in the two groups were lower than before treatment, while those in the observation group were lower than those in the control group (P<0.05); The serum MDA levels in both groups were lower than before treatment, while those in the observation group were lower than those in the control group (P<0.05); The serum SOD and GSH levels in both groups were higher than before treatment, while the observation group was higher than the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two group (P>0.05). 【Conclusion】 Xinmailong injection combined with Ribavirin has a better clinical effect in the treatment of viral Myocarditis with cardiac insufficiency, which can improve the cardiac function of patients and improve the oxidative stress state of the body.
|
|
Received: 23 July 2022
|
|
|
|
|
|
[1] 戚瑞雪,任川,袁丽霞,等.吸气肌训练联合耐力训练对病毒性心肌炎心衰患者心肺耐力及外周肌力的影响[J].中华医学杂志,2020,100(28):2211-2215.
[2] 王莲,吕为萍,丁艳,等. 葛根素注射液联合利巴韦林对病毒性心肌炎患儿免疫功能及炎症因子的影响[J].国际医药卫生导报,2020,26(5):697-700.
[3] 赵玲.心脉隆注射液联合重组人脑利钠肽治疗重症心肌炎伴心功能不全的临床疗效[J].中西医结合心脑血管病杂志,2019,17(16):2510-2512.
[4] 中华医学会儿科学分会心血管学组.病毒性心肌炎诊断标准(修订草案)[J].中国实用儿科杂志,2000,38(5):75.
[5] 中华医学会心血管病分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-117.
[6] ROBINSON J, HARTLING L, VANDERMEER B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults[J].Cochrane Database Syst Rev,2020,8(8):4370.
[7] 张学平,卢杏,李医博,等.曲美他嗪辅助利巴韦林治疗柯萨奇病毒感染致心肌炎伴心力衰竭的临床效果[J].天津药学,2021,33(3):46-48.
[8] 冯穗芬,魏毅,刘建辉,等.冠状病毒RNA聚合酶抑制剂:利巴韦林的构效关系分析[J].临床药物治疗杂志,2020,18(2):46-49.
[9] 路陆,王峰,杨静,等.血府逐瘀汤联合心脉隆注射液对急性冠脉综合征患者PCI术后NT-proBNP、CRP及心功能的影响[J].现代中西医结合杂志,2020,29(8):811-814.
[10] 曹书奎,金晓烨,赵晓,等.心脉隆注射液联合重组人脑利钠肽对ICU重症心肌炎伴心功能不全老年患者心肾功能及血流动力学指标的影响[J].中国医学工程,2021,29(6):54-57.
[11] 仝峰,司大妞,乔雯雯,等.心脉隆注射液治疗老年慢性心力衰竭的临床疗效及安全性分析[J].中国循证心血管医学杂志,2021,13(6):726-729.
[12] 王鑫,刘美林,贺少辉,等.重组人脑利钠肽与艾司洛尔联合对缺血性心力衰竭病人临床疗效及血液流变学、血清SOD、MDA水平的影响[J].中西医结合心脑血管病杂志,2018,16(12):1700-1703.
[13] 赵淑兰,刘培敏.不稳定心绞痛患者SOD、ox-LDL水平变化及与心功能、细胞因子水平的相关性研究[J].中华保健医学杂志,2019,21(1):66-68. |
|
|
|
2023, Vol. 40 
